Zobrazeno 1 - 10
of 299
pro vyhledávání: '"Jan Beyer‐Westendorf"'
Autor:
MacKenzie Horn, Ankur Banerjee, Linda Kasickova, Ondrej Volny, Hyun Seok Choi, Federica Letteri, Tomoyuki Ohara, Koji Tanaka, Stuart Connolly, Per Ladenvall, Mark Crowther, Jan Beyer‐Westendorf, Ashkan Shoamanesh, Andrew M. Demchuk, Abdulaziz S. Al Sultan, for the ANNEXa‐4 Investigators
Publikováno v:
Brain and Behavior, Vol 14, Iss 5, Pp n/a-n/a (2024)
Abstract Background and purpose The ANNEXA‐4 trial measured hemostatic efficacy of andexanet alfa in patients with major bleeding taking factor Xa inhibitors. A proportion of this was traumatic and nontraumatic intracranial bleeding. Different meas
Externí odkaz:
https://doaj.org/article/ff1fa63f153a4ca89ede25b0acd294e1
Autor:
Stephan Baldus, Jan Beyer-Westendorf, Helge Möllmann, Wolfgang Rottbauer, Elisabeth Beyerlein, Andreas Goette
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Approximately one fifth of patients diagnosed with atrial fibrillation (AF) undergo a percutaneous coronary intervention (PCI). Current guidelines recommend different combinations and durations of triple or dual antithrombotic therapy for th
Externí odkaz:
https://doaj.org/article/d98431a5a3ce469dbe164bdabd201b7f
Autor:
Reinhold Kreutz, Gilbert Deray, Jürgen Floege, Marianne Gwechenberger, Kai Hahn, Andreas R. Luft, Pontus Persson, Christoph Axthelm, Juerg Hans Beer, Jutta Bergler-Klein, Nicolas Lellouche, Jens Taggeselle, Jan Beyer-Westendorf
Publikováno v:
TH Open, Vol 08, Iss 01, Pp e106-e113 (2024)
Background Patients with atrial fibrillation (AF) and chronic kidney disease (CKD) are at high risk for both thromboembolism and bleeding events. The latter induces a potential reason for withholding oral anticoagulation (OAC) despite an indication f
Externí odkaz:
https://doaj.org/article/4a7ae1320e044c699c2d05521ca7813c
Autor:
Mauricio Concha, Lizhen Xu, MacKenzie Horn, Tomoyuki Ohara, Juliet Nakamya, Jan Beyer‐Westendorf, Ashkan Shoamanesh, Alexander Cohen, Per Ladenvall, Stuart J. Connolly, Andrew M. Demchuk
Publikováno v:
Stroke: Vascular and Interventional Neurology, Vol 4, Iss 1 (2024)
Background Andexanet alfa, a specific reversal agent for factor Xa inhibitors, resulted in effective hemostasis in 79% of patients with intracranial bleeding in the ANNEXA‐4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor
Externí odkaz:
https://doaj.org/article/9afe5c2bf3dd4bf3923c253ead8387eb
Autor:
Lars Heubner, Paul Leon Petrick, Andreas Güldner, Lea Bartels, Maximillian Ragaller, Martin Mirus, Axel Rand, Oliver Tiebel, Jan Beyer-Westendorf, Martin Rößler, Jochen Schmitt, Thea Koch, Peter Markus Spieth
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-16 (2022)
Abstract Acute Respiratory Distress Syndrome (ARDS) is common in COVID-19 patients and is associated with high mortality. The aim of this observational study was to describe patients’ characteristics and outcome, identifying potential risk factors
Externí odkaz:
https://doaj.org/article/a24b5597c76a42c484158ad6af520d53
Autor:
Lars Heubner, Marvin Greiner, Oliver Vicent, Jan Beyer-Westendorf, Oliver Tiebel, Ute Scholz, Andreas Güldner, Martin Mirus, Dietmar Fries, Thea Koch, Peter Markus Spieth
Publikováno v:
Thrombosis Journal, Vol 20, Iss 1, Pp 1-16 (2022)
Abstract Background SARS-CoV-2 infections are suspected to trigger the coagulation system through various pathways leading to a high incidence of thromboembolic complications, hypercoagulation and impaired fibrinolytic capacity were previously identi
Externí odkaz:
https://doaj.org/article/4d92a0b3c3ca424c9cd2ad74b1cf30bd
Autor:
Christina Köhler, Luise Tittl, Ulrike Hänsel, Evelyn Hammermüller, Sandra Marten, Christiane Naue, Marianne Spindler, Laura Stannek, Kristina Fache, Jan Beyer-Westendorf
Publikováno v:
TH Open, Vol 07, Iss 03, Pp e251-e261 (2023)
Background Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism (VTE) treatment or stroke prevention in atrial fibrillation. Major surgical procedures are not uncommon in anticoagulated patients but data
Externí odkaz:
https://doaj.org/article/43c89c41fa64416fb4b363d67f8ad1e0
Autor:
Olivia S. Costa, Stuart J. Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J. Christoph, Belinda Lovelace, Craig I. Coleman
Publikováno v:
Critical Care, Vol 26, Iss 1, Pp 1-13 (2022)
Abstract Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding. Four-factor proth
Externí odkaz:
https://doaj.org/article/5a95a8a8d12246ddbc13b48e098b4962
Autor:
Waltraud Pfeilschifter, Edelgard Lindhoff-Last, Ali Alhashim, Barbara Zydek, Simone Lindau, Stavros Konstantinides, Oliver Grottke, Ulrike Nowak-Göttl, Christian von Heymann, Ingvild Birschmann, Jan Beyer-Westendorf, Patrick Meybohm, Andreas Greinacher, Eva Herrmann, the RADOA-Registry Investigators (Reversal Agent use in patients treated with Direct Oral Anticoagulants or vitamin K antagonists Registry)
Publikováno v:
Neurological Research and Practice, Vol 4, Iss 1, Pp 1-7 (2022)
Abstract Background and purpose The use of direct oral anticoagulants (DOAC) has increased sharply and DOAC are the oral anticoagulant therapy (OAT) of choice for the majority of patients with newly-diagnosed atrial fibrillation. Intracranial hemorrh
Externí odkaz:
https://doaj.org/article/e2692267b3564bf7aed7eb40465da227
Autor:
Craig I. Coleman, Olivia S. Costa, Stuart J. Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J. Christoph-Schubel, Belinda Lovelace
Publikováno v:
Critical Care, Vol 27, Iss 1, Pp 1-2 (2023)
Externí odkaz:
https://doaj.org/article/4e44f0a675cb47fdb0520df4c3ddba7c